

ADVISORY NOTE

---

# Global Nicotine Reduction Strategy

---

WHO Study Group on Tobacco Product Regulation (TobReg)



World Health  
Organization

WHO Library Cataloguing-in-Publication Data

---

Advisory note: global nicotine reduction strategy: WHO Study Group on Tobacco Product Regulation.

1.Nicotine – administration and dosage. 2.Tobacco – chemistry. 3.Smoking – prevention and control. 4.Behaviour, Addictive. 5.Tobacco Products. 6.Dose-Response Relationship, Drug. 7.Tobacco Industry. I.World Health Organization. II.WHO Study Group on Tobacco Product Regulation.

ISBN 978 92 4 150932 9

(NLM classification: WM 290)

---

**© World Health Organization 2015**

All rights reserved. Publications of the World Health Organization are available on the WHO website ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website ([www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

ADVISORY NOTE

---

# **Global Nicotine Reduction Strategy**

---

WHO Study Group on Tobacco Product Regulation (TobReg)



**World Health  
Organization**

# Contents

|   |    |
|---|----|
| Participants  | 5  |
| Acknowledgements  | 8  |
| Preface   | 10 |
| Main recommendations  | 12 |
| Significance for public health  | 13 |
| Implications for WHO programmes   | 13 |
| Reducing the addictiveness of manufactured cigarettes by<br>reducing their nicotine content: research needs and regulatory<br>recommendations | 15 |
| 1. Introduction   | 15 |
| 2. Background   | 16 |
| 3. Cigarettes with a reduced nicotine content   | 16 |
| 4. Goals of a policy to reduce addiction to cigarettes  | 17 |
| 5. Tobacco addictiveness factors  | 17 |
| 6. Establishing a performance standard for nicotine products  | 19 |
| 7. Feasibility of reducing nicotine   | 21 |
| 8. Potential behavioural and population outcomes  | 22 |
| 9. Policy approaches to nicotine reduction  | 23 |
| 10. Conclusions   | 27 |
| 11. Research needs  | 27 |
| 12. Regulatory recommendations  | 28 |
| 13. References  | 30 |

# **Participants in the seventh meeting of the WHO Study Group on Tobacco Product Regulation**

**Rio de Janeiro, Brazil, 4–6 December 2013**

## **Members**

Dr D.L. Ashley, Director, Office of Science, Center for Tobacco Products, US Food and Drug Administration, Rockville, Maryland, United States of America

Professor O.A. Ayo-Yusuf, Dean, School of Oral Health Sciences, Sefako Makgatho Health Sciences University, Pretoria, South Africa

Professor A.R. Boobis, Biochemical Pharmacology, Centre for Pharmacology and Therapeutics, Department of Medicine, Imperial College, London; Director, Public Health England Toxicology Unit, Imperial College, London, United Kingdom

Dr M.V. Djordjevic, Program Director/Project Officer, Tobacco Control Research Branch, Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, United States of America

Dr N. Gray, Honorary Senior Associate, Cancer Council Victoria, Melbourne, Australia†

Dr P. Gupta, Director, Healis Sekhsaria Institute for Public Health, Mumbai, India

Dr S.K. Hammond, Professor of Environmental Health Sciences, School of Public Health, University of California, Berkeley, California, United States of America

Dr J. Henningfield, Professor (Adjunct), Behavioral Biology, The Johns Hopkins University School of Medicine; Vice President, Research, Health Policy, and Abuse Liability Pinney Associates, Bethesda, Maryland, United States of America

Dr D. Hatsukami, Professor of Psychiatry, University of Minnesota, Minneapolis, Minnesota, United States of America

Dr A. Opperhuizen, Director, Office for Risk Assessment and Research, Utrecht, The Netherlands

Dr G. Zaatari (Chair), Professor and Chairman, Department of Pathology and Laboratory Medicine, American University of Beirut, Beirut, Lebanon

### **Contributors**

Dr E. Akl, Associate Professor of Medicine, Department of Internal Medicine, American University of Beirut, Lebanon

Dr T. Eissenberg, Professor of Psychology and Co-Director, Center for the Study of Tobacco Products, Virginia Commonwealth University, Richmond, Virginia, United States of America

Dr W. Maziak, Professor and Chair, Department of Epidemiology, Florida International University; Director, Syrian Center for Tobacco Studies, Miami, Florida, United States of America

Dr P. Mehrotra, Senior Programme Officer, Population Council, New Delhi, India

Mr J. Morton, Senior Survey Methodologist, Global Tobacco Control Branch, Office on Smoking and Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

Dr A. Shihadeh, Professor of Mechanical Engineering, Faculty of Engineering and Architecture, American University of Beirut, Beirut, Lebanon

### **Facilitors of the WHO FCTC Conference of the Parties Working Group on Articles 9 and 10**

Dr P. Altan, Tobacco Control Department, Ministry of Health, Ankara, Turkey

Ms A.C. Bastos de Andrade, Head of Tobacco Products Control Department, Agência Nacional de Vigilância Sanitária, Rio de Janeiro, Brazil

Dr Katja Broman, Policy Officer, Tobacco Control Team, European Commission, Directorate-General for Health and Consumers, Unit D4, Substances of Human Origin and Tobacco Control, Brussels, Belgium

Mr D. Choinière, Director, Tobacco Products Regulatory Office, Controlled Substances and Tobacco Directorate, Health Canada, Ottawa, Ontario, Canada

### **Presenters**

Dr G. Ferris Wayne, California, United States of America

Dr R. Grana, Postdoctoral Fellow, Center for Tobacco Control Research and Education, University of California, San Francisco, California, United States of America

Dr M. Parascandola, Epidemiologist, Tobacco Control Research Branch, Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Maryland, United States of America

Dr R. Talhout, National Institute for Public Health and Environment, Centre for Health Protection, Bilthoven, The Netherlands

### **Convention Secretariat of the WHO FCTC (Geneva, Switzerland)**

Ms K. Brown, Programme Officer

### **WHO Regional Office for the Americas**

Dr A. Blanco, Regional Advisor, Tobacco Control, Washington DC, United States of America

### **WHO Secretariat (Tobacco Free Initiative, Prevention of Noncommunicable Diseases, Geneva, Switzerland)**

Ms M. Aryee-Quansah, Administrative Assistant

Dr A. Peruga, Programme Manager

Dr V.M. Prasad, Project Manager

Ms G. Vestal, Technical Officer (Legal)

## Acknowledgements

WHO has many people to thank for the production of this WHO Study Group on Tobacco Product Regulation (TobReg) Advisory Note on Global Nicotine Reduction Strategy. Ms Gemma Vestal coordinated the production, with the supervision and support of Dr Armando Peruga and Dr Douglas Bettcher.

Work on the advisory note began shortly after the fifth session of the Conference of the Parties to the WHO Framework Convention on Tobacco Control (WHO FCTC) in Seoul, Republic of Korea, 12–17 November 2012, and continued after the sixth session, in Moscow, Russian Federation, 13–18 October 2014.

We thank all the members of TobReg for their full, whole-hearted dedication, time and unfailing commitment to fulfilling their mandate to advise WHO on tobacco product regulation, a highly complex area of tobacco control. As independent experts, members of TobReg serve WHO without remuneration. In response to the requests to WHO made by the Conference of the Parties at its fifth session, TobReg members provided guidance in drafting the terms of reference for commissioning a series of reviews to serve as background documents and as a basis for discussions at TobReg's seventh meeting, held in Rio de Janeiro, Brazil, in December 2013. The TobReg recommendations on these issues were published as Technical Report Series 989 (WHO, 2015), which was presented by the Director-General of WHO to the 136th session of the Executive Board, held in Geneva, Switzerland, on 25 January to 3 February 2015.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_27283](https://www.yunbaogao.cn/report/index/report?reportId=5_27283)

